• Clarithromycin (A4322): Ensuring Reliable CYP3A Inhibition i

  2026-05-28

  This article demystifies laboratory challenges in CYP3A inhibitor studies, focusing on how Clarithromycin (SKU A4322) delivers reproducible, data-driven solutions for drug-drug interaction and pharmacokinetic research. Drawing from real-world laboratory scenarios, we highlight best practices, protocol insights, and vendor selection considerations for biomedical researchers and technicians.

• Lanabecestat (AZD3293) in Alzheimer’s: Protocols & Innovatio

  2026-05-28

  Lanabecestat (AZD3293) stands out as a potent, blood-brain barrier-penetrant BACE1 inhibitor, enabling precise amyloid-beta modulation in Alzheimer's disease research. This article details advanced experimental workflows, troubleshooting strategies, and the latest evidence on synaptic safety, empowering researchers to optimize their studies with confidence.

• Erlotinib (NSC 718781): Applied EGFR Inhibition in Cancer Mo

  2026-05-27

  Erlotinib (NSC 718781) empowers translational researchers to dissect EGFR-driven oncogenic signaling and overcome resistance associated with SCUBE3. This article details advanced workflows, troubleshooting, and protocol enhancements that maximize the impact of APExBIO's Erlotinib in preclinical and mechanistic oncology research.

• ZCL278: Precision Control of Cdc42 Signaling in Cellular Mod

  2026-05-27

  Discover how ZCL278, a selective Cdc42 inhibitor, enables refined dissection of cell motility, neuronal branching, and disease signaling. This article uniquely connects mechanistic insights with advanced assay design and translational research opportunities.

• SP2509: Advancing Epigenetic Therapy in Acute Myeloid Leukem

  2026-05-26

  This article explores the mechanistic depth and translational significance of SP2509, a next-generation Lysine-specific demethylase 1 antagonist, in the context of acute myeloid leukemia (AML) research. By integrating recent mechanistic insights, competitive landscape analysis, and evidence-based protocol recommendations, it offers strategic guidance for researchers aiming to harness SP2509’s unique properties to drive advances in cancer epigenetics.

• Synergistic Induction of Lysosomal Cell Death in RCC via SGI

  2026-05-26

  This study uncovers a novel synergy between the DNMT1 inhibitor SGI-1027 and the mTOR inhibitor everolimus, demonstrating that their combination triggers apoptosis and GSDME-dependent pyroptosis in renal cell carcinoma by promoting lysosomal membrane permeability. These mechanistic insights highlight new opportunities for overcoming everolimus resistance in advanced RCC.

• Stiripentol: LDH Inhibitor Workflows for Epilepsy & Metaboli

  2026-05-25

  Stiripentol, a potent noncompetitive LDH inhibitor, enables researchers to precisely modulate lactate metabolism in both epilepsy and tumor immunometabolism studies. This guide synthesizes recent breakthroughs, providing stepwise protocols, troubleshooting strategies, and comparative insights to maximize the impact of Stiripentol in advanced research applications.

• T0070907: Redefining PPARγ Antagonism for Translational Rese

  2026-05-25

  Explore how T0070907, a nanomolar PPARγ antagonist, empowers translational researchers to dissect senescence, inflammation, adipogenesis, and cancer cell cycle arrest. This article bridges mechanistic insight from the RXRα/PPARγ/NEDD4 pathway with strategic protocol guidance and competitive product intelligence, advancing the translational relevance and experimental precision of PPARγ pathway inhibition.

• Exercise-Induced Muscle EVs Boost Microglial Amyloid Clearan

  2026-05-24

  This study reveals that skeletal muscle-derived extracellular vesicles (SKM-EVs), released in response to exercise, are taken up by microglia and enhance amyloid-beta plaque clearance in Alzheimer's disease (AD) mouse models. The findings identify a muscle-to-brain communication pathway that mediates cognitive improvement and suggest new therapeutic and research strategies for targeting amyloid pathology.

• Amphotericin B (SKU B1885): Data-Backed Solutions for Assay

  2026-05-23

  This article provides a scenario-driven, evidence-based guide for using Amphotericin B (SKU B1885) to overcome common laboratory challenges in cell viability, proliferation, and cytotoxicity assays. Drawing on quantitative data and practical workflow insights, it demonstrates how researchers can achieve reliable, reproducible results with APExBIO’s Amphotericin B.

• Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea) in Toxicolo

  2026-05-22

  Leverage high-purity Diuron from APExBIO to dissect herbicide mechanisms and nephrotoxicity with robust, reproducible workflows. This article translates cutting-edge findings into actionable protocols and troubleshooting insights for plant biology and environmental toxicology labs.

• Ceftazidime: Strategic Insights on Gram-Negative Resistance

  2026-05-22

  This thought-leadership article explores how Ceftazidime, a third-generation cephalosporin, empowers translational researchers to outmaneuver Gram-negative resistance in the post-pandemic era. Integrating mechanistic insights, recent genomic surveillance data, and protocol recommendations, it delivers a strategic roadmap for effective infection models and stewardship.

• AP20187: Chemical Inducer of Dimerization for Precision Gene

  2026-05-21

  AP20187 enables tunable, reversible protein interactions for next-generation conditional gene therapy and metabolic modulation. Its unparalleled solubility and rapid cell permeability make it the reagent of choice for regulated cell therapy and advanced in vivo studies, especially when dissecting signaling networks like 14-3-3-mediated cancer mechanisms.

• Talabostat Mesylate (PT-100): Protocols and Innovations in T

  2026-05-21

  Talabostat mesylate (PT-100) offers targeted inhibition of DPP4 and FAP, enabling advanced modulation of the tumor microenvironment and immune responses in cancer models. This guide details actionable experimental workflows, troubleshooting strategies, and new insights from recent inflammasome research, positioning Talabostat mesylate from APExBIO as a cornerstone for translational oncology studies.

• T0070907: Precision PPARγ Antagonist for Cellular Pathway Di

  2026-05-20

  T0070907 stands out as a potent, selective PPARγ antagonist, empowering researchers to unravel PPARγ-driven signaling in inflammation, adipogenesis, and cancer biology. This guide delivers actionable workflow enhancements and troubleshooting tips for robust, reproducible assays using T0070907 from APExBIO.

16088 records 1/1073 page Next 12345 下5页 Last page